Cite
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
MLA
Li, Hui, et al. “CDK12 Inhibition Enhances Sensitivity of HER2+ Breast Cancers to HER2-Tyrosine Kinase Inhibitor via Suppressing PI3K/AKT.” European Journal of Cancer, vol. 145, Mar. 2021, pp. 92–108. EBSCOhost, https://doi.org/10.1016/j.ejca.2020.11.045.
APA
Li, H., Wang, J., Yi, Z., Li, C., Wang, H., Zhang, J., Wang, T., Nan, P., Lin, F., Xu, D., Qian, H., & Ma, F. (2021). CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. European Journal of Cancer, 145, 92–108. https://doi.org/10.1016/j.ejca.2020.11.045
Chicago
Li, Hui, Jinsong Wang, Zongbi Yi, Chunxiao Li, Haijuan Wang, Jingyao Zhang, Ting Wang, et al. 2021. “CDK12 Inhibition Enhances Sensitivity of HER2+ Breast Cancers to HER2-Tyrosine Kinase Inhibitor via Suppressing PI3K/AKT.” European Journal of Cancer 145 (March): 92–108. doi:10.1016/j.ejca.2020.11.045.